Safety Profile and Tolerability

22 Oct 2026 0 comments

The panelists discuss the safety profile of zorevunersen, highlighting the low rate of treatment discontinuations, the nature of CSF protein elevation as an asymptomatic laboratory finding, and why the safety conversation with families is fundamentally different from any discussion about standard antiseizure medications.

Source: NeurologyLive Published 22 Oct 2026 Imported 22 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment